Juvaris BioTherapeutics
Today in the world we have many new forms of diseases. Cancer is the most dangerous and insidious scourge. To treat cancer we should spend plenty of time and money and there is a great field of work. Juvaris BioTherapeutics, Inc. is a company, located in Pleasanton, California, which develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer and helps both human and animals. Company was registered in 2001 with total amount of employees approximately 50 persons. It provides JVRS-100, a cationic lipid-DNA complex and adjuvant that improves the efficiency of present vaccines, as well as helps in improvement vaccines against infectious diseases. The company’s product is also used for treatment of virus, bacterial, and cancer diseases.
Martin D. Cleary was the first Chairman, Founder, President and CEO of the company from 2003. From 1999 to 2003, Mr. Cleary held office as a President, CEO and Director of Genteric, Inc. advancing its therapeutic protein delivery technology platforms. Under his leadership, the company earned $29 million in two venture investments. His successor, Grant E. Pickering, became the main Director and CEO afterwards. Before working with Juvaris, he founded Pharmada, corporation with cancer research center, and was its CEO and Director. His company dealt with medicine with small molecules for cancer treatment. Between 2000 and 2005 he worked for Dendreon corporation where he headed clinical development, marketing and project management. He gained his B.S. degree in marketing in The Pennsylvania State University.
Juvaris made an agreement with Colby Pharmaceutical Company in 2011, and the Company permitted unique, worldwide rights to improve and commercialize Juvaris' adjuvanted vaccine and immunotherapy tech. in the sphere of human health. In return for the license, Colby gave to Juvaris cash, main stages to expand and authorization on product sales. In addition, Colby will carried all development and commercialization-connected costs and maintain certain constant expenses and shouldered certain obligations of Juvaris. In addition, the Company has a contract with Bayer Healthcare AG, signed in 2008, providing broad exclusive rights to develop and monetize Juvaris technology in the field of animal health, in return for significant up-front payments, milestone payoffs and oncoming royalties on product spreading. Under the conditions of the agreement, Bayer HealthCare AG has full access to develop Juvaris' immunotherapy and vaccine technology in the sphere of animal health.
The Company's main products are Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100. JVRS-100 is an adjuvant, stimulates adaptive and congenital immune responsiveness at levels many times higher than other medicines of that category. JVRS-100 is now in clinical improvement and trials as a vaccine adjuvant and an immunotherapeutic. However, it is already being used for killing viruses and now the staff of the company is working on improving the efficiency of seasonal influenza vaccines. New types of products are launched as soon as they are developed. Seasonal influenza affects near one billion people each year resulting in 5 million serious diseases and 500,000 deaths. About 90 percent of the deaths happen to elder people, where flu infection can lead to severe complications from listed diseases, pneumonia and death. Seasonal influenza vaccines, used by citizens of the U.S. and developed countries, are efficient in only 30 percent of the elderly population. This creates for the company a potential target market. Fundraising of the company is good enough to create such drugs, the question is only how fast the new forms of medicine will be developed.
On the official web-site you can find many press releases of the company. You can track the main events of it: agreements with other corporations, financing, strategic collaborations, alliance with other health institution, data from clinical trial.
Juvaris BioTherapeutics Announces License to Colby Pharmaceutical Company for JVRS-100 and CLDC (Cationic Lipid-DNA Complex) Platform for Human Health — 09.09.11 (Juvaris BioTherapeutic,2014)1
Juvaris BioTherapeutics Announces Publication of Preclinical Anti-Leukemic Effects of JVRS-100 Immunotherapy — 09.30.10 (Juvaris BioTherapeutic,2014)1
Juvaris BioTherapeutics Completes Second Close on $25 million Series B Financing — 01.27.10 (Juvaris BioTherapeutic,2014)1
References
Juvaris BioTherapeutics (2014)1. Retrieved from http://www.juvaris.com/news/press.html
Juvaris BioTherapeutics (2014). Retrieved from http://www.juvaris.com/about/overview.html
Calisha Myers. ( January 8, 2009). Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine. FierceBiotech Retrieved from http://www.fiercebiotech.com/biotech/juvaris-biotherapeutics-announces-positive-data-from-clinical-trial-of-jvrs-100-adjuvanted
